Literature DB >> 16940056

Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez.   

Abstract

Tigecycline was tested against 396 strains of lesser-known anaerobic species encountered in human infections. It was active against all gram-positive strains and 228 of 232 gram-negative anaerobes at < or =1 microg/ml. One strain of Prevotella oralis was nonsusceptible at 8 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940056      PMCID： PMC1610075          DOI： 10.1128/AAC.00499-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

4.  Diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Jack L LeFrock; Daniel P Lew; Jon T Mader; Carl Norden; James S Tan
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

5.  In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Authors:  C Edlund; C E Nord
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

6.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.

Authors:  E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

8.  In vitro activity of tigecycline against Bacteroides species.

Authors:  C Betriu; E Culebras; M Gómez; I Rodríguez-Avial; J J Picazo
Journal:  J Antimicrob Chemother       Date:  2005-06-10       Impact factor: 5.790

9.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

10.  In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803
View more
  8 in total

1.  Successful tigecycline lock therapy in a Lactobacillus rhamnosus catheter-related bloodstream infection.

Authors:  F Bartalesi; S Veloci; F Baragli; E Mantengoli; S Guidi; A M Bartolesi; R Mannino; P Pecile; A Bartoloni
Journal:  Infection       Date:  2011-10-18       Impact factor: 3.553

Review 2.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 3.  Actinomyces and related organisms in human infections.

Authors:  Eija Könönen; William G Wade
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 4.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 5.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

6.  Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Authors:  Lauren M Castner; Madsen Zimbric; Shannon Cahalan; Corey Powell; Lindsay J Caverly
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

7.  Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.

Authors:  Mary L Townsend; Melanie W Pound; Richard H Drew
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

8.  Antimicrobial Susceptibility of Clinical Oral Isolates of Actinomyces spp.

Authors:  Alexandra Wolff; Arne C Rodloff; Paul Vielkind; Toralf Borgmann; Catalina-Suzana Stingu
Journal:  Microorganisms       Date:  2022-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.